Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sotrovimab (VIR 7831), a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), effectively neutralizes SARS-CoV-2, SARS-CoV-1, and various other sarbecoviruses. Developed from S309, it possesses a prolonged half-life and excellent bioavailability within the respiratory mucosa. Its mechanism potentially facilitates immune-mediated viral elimination, thereby averting the advancement of Covid-19 during the disease's early stages [1][2].
説明 | Sotrovimab (VIR 7831), a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), effectively neutralizes SARS-CoV-2, SARS-CoV-1, and various other sarbecoviruses. Developed from S309, it possesses a prolonged half-life and excellent bioavailability within the respiratory mucosa. Its mechanism potentially facilitates immune-mediated viral elimination, thereby averting the advancement of Covid-19 during the disease's early stages [1][2]. |
分子量 | N/A |
CAS No. | 2423014-07-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sotrovimab 2423014-07-5 Inhibitor inhibitor inhibit